STOCK TITAN

Kestra Medical officer proposes $312K share sale

Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
144

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) lists Brian Webster, an officer and director, for a proposed sale of 15,000 common shares, with an approximate sale date of June 15, 2026 and aggregate market value of $312,142.94. The shares were acquired January 21, 2026 through a restricted share issuance under the issuer’s equity compensation plan. The notice lists September 29, 2025 as the Rule 10b5-1 plan adoption date. Four prior sales of 15,000 shares each are listed for February 17, March 17, April 15 and May 15, 2026.

Proposed sale 15,000 common shares Approximate sale date June 15, 2026
Aggregate market value $312,142.94 Proposed sale
Common shares outstanding 58,373,353 shares As stated in the notice
Gross proceeds $384,020.06 Sale on February 17, 2026
Gross proceeds $304,123.49 Sale on March 17, 2026
Gross proceeds $300,671.04 Sale on April 15, 2026
Gross proceeds $314,329.85 Sale on May 15, 2026
Rule 10b5-1 regulatory
"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Aggregate Market Value financial
"Number of Shares or Other Units To Be Sold | Aggregate Market Value"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Restricted share issuance financial
"Nature of Acquisition Transaction | Restricted share issuance"
equity compensation plan financial
"Granted as part of issuer equity compensation plan"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KMTS shares does Brian Webster plan to sell?

Brian Webster, identified as an officer and director, is listed for a proposed sale of 15,000 common shares, with an approximate sale date of June 15, 2026 and aggregate market value of $312,142.94. The notice lists September 29, 2025 as the Rule 10b5-1 plan adoption date.

What were Brian Webster’s recent KMTS share sales?

Four prior sales are listed: 15,000 shares on February 17, 2026 for $384,020.06; 15,000 shares on March 17, 2026 for $304,123.49; 15,000 shares on April 15, 2026 for $300,671.04; and 15,000 shares on May 15, 2026 for $314,329.85.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading